ArticleTargeted oncology2017
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
Article in Targeted oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Corticosteroid-resistant immune-related adverse events: a systematic review.Journal for immunotherapy of cancer · 2024Pooled it
- Hemoperitoneum detected by peritoneal dialysis as presenting symptom of cytomegalovirus-associated colitis: a case report.BMC nephrology · 2026Article
- Article
- Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer.The Korean journal of internal medicine · 2025Article
- Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer.Cancers · 2024Article
- New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis.World journal of clinical cases · 2024Review
- Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure.Journal of cancer research and clinical oncology · 2023Article
- Review
- Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical Challenge.Cancers · 2023Review
- Article
- Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis.Biomedicines · 2022Review
- Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.Clinical and translational science · 2022Article
- [Oncological emergencies with special consideration of the side effects of checkpoint inhibitors].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2022Article
- The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma.Internal medicine (Tokyo, Japan) · 2022Article
- Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma.The Eurasian journal of medicine · 2022Article
- Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis.Biologics : targets & therapy · 2022Review
- Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer.Clinical journal of gastroenterology · 2021Article
- Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis.Virchows Archiv : an international journal of pathology · 2021Article
- Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021Review
- Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.Journal for immunotherapy of cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors are monoclonal antibodies indicated for an increasing number of malignant diseases. These agents can cause specific side effects, which need to be anticipated while clear patterns of management need to be established. Immune checkpoint inhibitor-mediated gastrointestinal side effects, including diarrhea and colitis, occur in up to 30% of patients. Severe colitis can lead to severe dehydration or intestinal perforation. Endoscopic lesions and histopathological features of immune checkpoint inhibitor-induced colitis are similar to an inflammatory bowel disease (IBD) flare. Patients with immune checkpoint inhibitor-induced diarrhea and colitis are treated with corticosteroids. Infliximab can be used in cases of corticosteroid failure. Rectosigmoïdoscopy or colonoscopy should be performed when severe immune checkpoint inhibitor-induced colitis is suspected, but endoscopic investigations should not delay treatment. Specific patient education as well as co-operation between oncologists and gastroenterologists is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.